OCUP News and Press, Ocuphire Pharma Inc Com From 05/18/21

The USPTO has issued two patents covering Ocuphire Pharma's (OCUP) late-stage product candidate, Nyxol (phentolamine mesylate).Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Book:Nyxol for Treatment of Presbyopia: U.S. Patent No. 10,...

Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol ® Combination Therapy for Presbyopia Provides Broader Protection for Nyxol ® Across Indications on Methods of Use as Daily Administration FARMINGTON HILLS, Mich. , May 18, 2...

Ocuphire recently became publicly traded in November 2020 after a reverse merger with Rexahn Pharmaceuticals. Ocuphire has a suite of ophthalmology products targeting both front and back of the eye indications, including one that just readout positive Phase 3 results. Although sev...

Ocuphire Pharma (OCUP) has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of a combination kit of Nyxol and low-dose pilocarpine in presbyopia, an eye disease associated with aging.A total of 150 subjects (planned tar...

Nyxol has Potential to be a New Eye Drop Treatment Option for Presbyopia Top-Line VEGA-1 Data Expected by End of Q2 2021 FARMINGTON HILLS, Mich., May 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinic...

Ocuphire Pharma (OCUP): Q1 Non-GAAP EPS of -$0.47 beats by $0.36; GAAP EPS of -$3.57.As of March 31, 2021, the Company had cash and cash equivalents of approximately $10.6 million.Press Release For further details see: Ocuphire Pharma EPS beats by $0.36

Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication Demonstrated Execution Capability with Four Phase 3 and 2 Clinical Trials Initiated and/or Completed i...

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization New Data from Physiological-Based Pharmacokinetic (PBPK) Model Supports APX3330 Oral Dose for the Ongoing ZETA-1 Phase 2 Trial FARMINGTON H...

Ocuphire Pharma (OCUP) announces that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy ((NPDR)) and mild proliferative diabetic retinopathy ((mild PDR)).The company said that topline data from the study is expected by e...

APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy Top Line Data from ZETA-1 Expected by Early 2022 FARMINGTON HILLS, Mich., April 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma,...